Furthermore, approximately 1 in 5 patients with BRAF mutant melanoma shows progression at first assessment during treatment, due to intrinsic/primary resistance in their tumors [6, 7] indicating that the mutational status of the target oncogene is insufficient to predict responsiveness to therapy. This evidence concerns the gene BRAF and melanoma.